Physiologic changes due to disease status can lead to highly variable pharmacokinetics (PK) of amikacin in children. Therefore, considerations should be given when determining optimal amikacin does for patients with a specific diseases. Improved understanding of factors influencing PD can allow for the optimizing of dosage regimens to reduce adverse effects.
The aim of the study was to undertake a comparative pharmacometic analysis of amikacin use in pediatric patients with burn injuries verses those with oncology conditions.
Kagan, R. J.,
Healy, D. P.,
& Sherwin, C. M.
(2016). Amikacin Pharmacokinetics in Pediatric Patients with Burn Injuries Compared to Those with Oncology Conditions. .